Connect with us

Subscribe

vaccine
Photo by Crawford Jolly on Unsplash

biotech

COVID-19 vaccine 90% effective

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.” The words of Dr Albert Bourla, Chairman and CEO of Pfizer, the company, along with BioNTech, behind the vaccine candidate that today was revealed to be 90% effective in preventing COVID-19.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” Dr Bourla said. “With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

Submissions for Emergency Use Authorization (EUA) are expected to be made to the U.S. Food and Drug Administration (FDA) in the third week of November. And it expected that up to 50 million vaccine doses will be available this year and 1.3 billion doses in 2021.

Newsletter Signup

Susan Robertson
Written By

Susan is the co-founder of Innovators Magazine and a consultant for OnePoint5 Media. Susan is also a member of the UNFCCC-led Resilience Frontiers Nexus group and a board member of the APOPO Foundation UK.

Women innovators being short-changed

Editor's Picks

Europe prioritises innovation

biotech

global global

Get to grips with the Global Goals

circular

inside inside

How we save the planet…

food | water

Connect
Newsletter Signup